Melanotan II (10mg Vial) Dosage Protocol
Table of Contents
Quickstart Highlights
Melanotan II 10mg dosage protocol is commonly researched for its potential effect on melanogenesis (tanning) and other physiological pathways, via daily subcutaneous injections.
- Typical starting dose of 250–500 mcg (0.25–0.5 mg) per day
- Daily injection schedule for steady melanocortin receptor activation
- Gradual increase to reduce side effects (e.g., nausea, flushing)
- Reconstitute with up to 3 mL for accurate measurement
- Store lyophilized in the freezer; reconstituted in the refrigerator
Dosing & Reconstitution Guide
Educational guide for reconstitution and dosing protocol
Standard / Gradual Approach (3 mL = ~3.33 mg/mL)
| Week | Daily Dosage (mcg) | Units (per injection) |
|---|---|---|
| Weeks 1–2 | 250 mcg | ~7.5 units |
| Weeks 3–4 | 500 mcg | ~15 units |
| Weeks 5–6 | 1 mg | ~30 units |
For gradual dose escalation. Reconstitute with 3 mL to achieve a concentration of approximately 3.33 mg/mL (3,333 mcg/mL).
Note: The 250 mcg dose yields ~7.5 units, which is below 10 units on a 100-unit syringe. Consider using smaller insulin syringes (e.g., 50-unit or 30-unit) for better precision.
- Draw 3.0 mL of bacteriostatic water into a sterile syringe.
- Inject the water slowly along the vial wall to reduce foaming.
- Gently swirl the vial—avoid vigorous shaking.
- Store the reconstituted solution at 2–8 °C (refrigerator), protected from light.
Advanced / Aggressive Approach (2 mL = 5 mg/mL)
| Week | Daily Dosage (mcg) | Units (per injection) |
|---|---|---|
| Weeks 1–2 | 500 mcg | ~10 units |
| Weeks 3–4 | 1 mg | ~20 units |
| Weeks 5–6 | 1.5 mg | ~30 units |
Recommended for users who are comfortable with higher initial doses. Reconstitute with 2 mL, creating a 5 mg/mL (5,000 mcg/mL) solution.
- Draw 2.0 mL of bacteriostatic water into a sterile syringe.
- Slowly inject the water down the vial wall to minimize foam.
- Gently roll/swirl the vial—no vigorous shaking.
- Store the reconstituted solution at 2–8 °C (refrigerator), protected from light.
Protocol Overview
A concise summary of this daily subcutaneous regimen.
- Goal : Facilitate melanogenesis (tanning) and other research endpoints
- Schedule : Daily subcutaneous injections for 4–6 weeks or longer
- Dose Range : 250 mcg up to 1–1.5 mg daily
- Reconstitution : Use 2–3 mL for practical measuring
- Storage : Keep lyophilized vials frozen; refrigerate after reconstitution
Dosing Protocol
Suggested daily injection approach for safe titration and improved tolerance.
- Daily Dose : Start at 250–500 mcg; gradually increase as tolerated
- Frequency : Inject once per day subcutaneously
- Cycle Length : 4–6 weeks (extend as needed for maintenance)
- Maximum Dose: Often capped around 1–1.5 mg daily to minimize side effects
- Timing : Any time of day; consistency in daily schedule is recommended
Storage Instructions
Proper storage ensures peptide integrity.
- Lyophilized : Freeze until mixing (−20°C)
- Reconstituted : Refrigerate at 2–8°C
- Use within 30 days of reconstitution
- Avoid repeated freeze-thaw cycles
Suppilies Needed
Ensure you have these on hand for a 4–6 week cycle (longer cycles may require additional vials).
- Peptide Vials :
-
- 4 wks ≈ 1 vial
- 6 wks ≈ 2 vials (More if planning higher doses or longer protocols)
- Insulin Syringes :One per day (e.g., 4 wks ≈ 28 syringes)
- Bacteriostatic Water : 1× 30ml
- Alcohol Swabs: 1 box
Important Notes
Practical tips to enhance safety and efficacy.
- Always use new, sterile insulin syringes & rotate injection sites.
- Monitor skin changes closely, particularly moles or pigmentation spots.
- Observe for adverse reactions; consult a professional if concerns arise.
- Track progress throughout the protocol, adjusting dosage as recommended.
How This Works
Melanotan II is a synthetic analog of the alpha-melanocyte-stimulating hormone (α-MSH), interacting with melanocortin receptors.
- Melanocortin Activation : Influences skin pigmentation by stimulating melanin production
- Extended Research Areas : Potential roles in metabolic regulation and sexual function
- Commonly investigated for tanning and photoprotection effects
Potential Benefits & Side Effects
Users often observe accelerated tanning; side effects vary based on dosage and individual factors.
- Promotes deeper, more uniform skin pigmentation
- May support appetite suppression in some cases
- Side effects can include nausea, flushing, or increased libido
- In rare cases, can cause darkening of moles or freckles
Lifestyle Factors
Complementary strategies for maximum benefit.
- Maintain a balanced diet rich in nutrients
- Use appropriate sun protection to avoid overexposure
- Stay hydrated and follow a consistent sleep schedule
Injection Technique
Simple guidelines for safe daily injections.
- Clean vial rubber stopper & injection site with alcohol swabs
- Insert needle at a 45–90° angle into subcutaneous tissue
- Inject slowly & rotate sites (abdomen, thigh, etc.)
Recommended Source
We recommend Go Alpha Labs for high-purity Melanotan II.
Why Go Alpha Labs?
- Verifies ≥99% purity through independent lab testing
- Trusted by researchers seeking reliable results
- Follows rigorous manufacturing standards for consistent quality
Important Note:
This guide is for educational purposes only. Always consult a qualified healthcare provider before starting or modifying any therapy.
References:
| Source | Link |
|---|---|
| PubMed – Melanotan II preliminary clinical study | View Source |
| PubMed Central – Study on synthetic melanocortin analog | View Source |
| PubMed – Melanocortin receptor research findings | View Source |
| AHA Journals – Metabolic pathway exploration | View Source |
| PubMed Central – Peptide efficacy in vivo | View Source |
| Karger – Melanotan II user experience study | View Source |
| PubMed Central – Clinical data on peptide usage | View Source |
| PubMed – Melanotan II pharmacodynamics study | View Source |
| JAMA Dermatology – Dermatological outcomes of melanotan | View Source |
| Pfizer Labeling – Official labeling documentation | View Source |
| Alberta Health – Guidance on post-care instructions | View Source |
| TGA.gov.au – Australian regulator caution on melanotan | View Source |
| TGA.gov.au – Scheduling delegates interim decisions | View Source |
| HPRA – Health Products Regulatory Authority warning | View Source |
| DermNet NZ – Resource on melanotan research | View Source |
| Actas Dermo-Sifiliográficas – Spanish dermatology article | View Source |
| Drugs.ie – Irish resource on tanning agents | View Source |
| Oxford Academic – British Journal of Dermatology study | View Source |
| Wiley Online Library – Analytical toxicology of peptides | View Source |
| Physiological Society – Peer-reviewed physiology paper | View Source |